Projectes

Codi

101129375

Investigador/a principal

Lucas Krauel Giménez-Salinas

Rol

Participant

Any d'inici

2023

Any de finalització

2026

Import total

35952€

Objectius

The INTERACT2 project aims at implementing the Inter-specialty Cancer Training (ISCT) curriculum developed under the INTERACTEUROPE project. The objective of the ISCT programme is to foster a patient-centric approach to quality cancer care through the promotion of multidisciplinary and multi-professional teams working across Europe. The project will critically review the current state
of inter-specialty training resources, identify existing quality learning materials and produce innovative learning resources to meet the requirements of the ISCT curriculum and ensure the needs of oncology patients across Europe are addressed. In the framework of the project, two new modules focusing on paediatric oncology and the specific needs of Ukrainian displaced healthcare professionals
and people in care will be developed. A dedicated digital learning management system adapted to the needs of oncology professionals will be established to support the decentralised implementation of the ISCT programme for trainers and trainees at the national level. The activities linked to the training of trainers will target experts in the fields of clinical oncology, surgery, radiation
oncology, cancer nursing and other specialised staff from at least 100 cancer centres in Europe and will ensure the future sustainability of the ISCT programme in EU Members States. Local and international events for trainers will facilitate the exchange of best learning practices and establish an EU network of inter-specialty cancer trainers to achieve best patient outcomes.

Codi

101081441

Investigador/a principal

Joan Sánchez de Toledo

Rol

Participant

Any d'inici

2023

Any de finalització

2028

Objectius

European Commission_Sanchez de Toledo, Joan

Codi

101119924

Investigador/a principal

Mónica Roldan Molina

Rol

Participant

Any d'inici

2023

Any de finalització

2027

Import total

217051,34€

Objectius

Photonics is crucial for maintaining and increasing the competitiveness of EU industry, and light-based instruments are fundamental for non-invasive diagnostics and treatment of diseases, delivering huge economic benefits for national health systems. Artificial
Intelligence (AI) and Machine Learning (ML) have demonstrated their capability to classify and identify patterns in data, achievingreliability levels that are comparable to those of experienced physicians.
To fully develop the potentials of these technologies, BE-LIGHT will provide top level training to 11 Researchers in photonic technologies (multispectral imaging, eye-tracking, optical coherence tomography, multispectral optoacoustic tomography, superresolution
microscopy and optogenetics) that will be complemented with AI/ML, computational imaging and modelling. A close-tothe- clinic approach will allow them to advance the field of biomedicine, with the ultimate goal of improving the understanding,
diagnosis and treatment of diseases in 3 main research areas: visual health, cardiovascular health, and analysis of cells and tissues (related to Parkinson’s and rare diseases) using super-resolution microscopy.
BE-LIGHT brings together an interdisciplinary consortium of 7 top academic institutions, 3 internationally recognized hospitals, and an ecosystem of 7 private companies with complementary know-how in photonics, microscopy, AI/ML, medical instruments and
clinical research, to promote inter-sectoral synergies.
BE-LIGHT’s multi-skill training program will provide the researchers with the complete set of skills that are nowadays key for their success in both academic and non-academic sectors. They will gain a broad understanding of how state-of-the-art light-based
technologies work, a solid knowledge of ML and data processing, and will obtain experience in clinical and commercialization processes. BE-LIGHT will open for them a wide range of high-quality job opportunities.

Codi

101094195

Investigador/a principal

Arnau Valls Esteve

Rol

Participant

Any d'inici

2023

Any de finalització

2026

Import total

918243,75€

Objectius

Cross-border collaboration can tackle the challenges in accessing relevant health data essential for international collaboration between scientists and clinicians, researchers, and health industry. Privacy concerns and regulations on personal data have made the sharing of health data increasingly complex and time-consuming for data controllers, thus severely limiting the access of SMEs,
researchers, and innovators to health data. Further complications in cross-border collaboration arise from differences in interpreting the EU GDPR, national regulations, and heterogenous and changing data permit processes at hospital sites.
The PHEMS project will provide European children’s hospitals with a decentralized and open health data ecosystem concept consisting of technical components and governance frameworks. The objective is to facilitate access to health data, advance federated health data analysis and build services for the on-demand generation of shareable, synthetized, and anonymized datasets.
To achieve this, the project will focus on bridging the gaps in data access and use, especially in the integration of ethical, legal, and technical requirements, including the responsibilities of data controllers and the rights of data subjects. This will allow health data controllers to engage in collaboration without losing control on compliance with respect to GDPR, national legislation or internal policies of their organization.
The techniques and tools for generating algorithmically anonymized and synthetic datasets will undergo robust validation processes through three clinical use cases conducted by the European Children’s Hospitals Organisation (ECHO) community. The goal is to assess the usage of custom-generated synthetic data with real-life questions. Data users, such as researchers, SMEs, innovators and the pharmaceutical and MedTech industry, will be engaged through community building, hackathons, and interaction with relevant European large-scale initiatives.

Codi

200047TG1

Investigador/a principal

Ana Maria Merino Márquez, Jordi Moretón Galí

Rol

Individual

Any d'inici

2023

Any de finalització

2025

Import total

66217,84€

Objectius

AGAUR_Ana Merino

Codi

101076506

Investigador/a principal

Alexandra Avgustinova

Rol

Individual

Any d'inici

2023

Any de finalització

2028

Import total

387086,09€

Objectius

Childhood cancers are believed to be rooted in aberrant development, a notion supported by their (i) generally low mutational burden, (ii) high prevalence of single (often epigenetic) driver events and (iii) occurrence during confined developmental periods. Yet, the exact origins of developmental tumours remain one of the principal enigmas of pediatric oncology.
A prime example are malignant rhabdoid tumours (MRTs): they are astoundingly genomically simple but extremely deadly childhood cancers that arise almost exclusively in the first two years of life, and are driven by biallelic inactivation of the SWI/SNF chromatin
remodelling complex subunit SMARCB1 (>95% of cases). We still do not know what determines oncogenic competence upon SMARCB1 loss. In particular we wonder: (1) What are the cell(s)- of-origin of rhabdoid tumours and what is their normal differentiation potential? (2) What is the molecular framework that facilitates oncogenic transformation upon SMARCB1 loss? (3) What is the contribution of the niche (local and systemic) to the acquisition of oncogenic competence? And, considering the epigenetic nature of the oncogenic event, (4) is the oncogenic MRT state reversible, and how?
To answer these questions, we will combine state-of-the-art lineage-barcoded single-cell genomics, spatial transcriptomics, single-cell resolution wholemount imaging, CRISPR/Cas9 and epigenomic approaches, as well as integrative computational analyses, using
transgenic mouse, induced pluripotent stem cell and patient-derived xenograft rhabdoid tumour models. This project will provide fundamental insights into the cell autonomous and non-autonomous determinants of oncogenic competence upon SMARCB1 loss. Based on our findings we hope to unlock targeted treatments for MRT patients. Importantly, the conceptual and experimental frameworkwe establish will open up new investigative opportunities for a multitude of developmental cancers.

Investigador/a principal

Alexandra Avgustinova

Rol

Individual

Any d'inici

2023

Any de finalització

2028

Codi

200010TC1

Investigador/a principal

Antoni Serrano Blanco

Rol

Individual

Any d'inici

2023

Any de finalització

2025

Import total

66217,84€

Objectius

AGAUR_Antoni Serrano

Codi

200010TG1

Investigador/a principal

Antonio Callen Soto

Rol

Individual

Any d'inici

2023

Any de finalització

2025

Import total

66217,84€

Objectius

AGAUR_Antoni Callén

Codi

200047TC1

Investigador/a principal

Alessandra Magnani

Rol

Individual

Any d'inici

2023

Any de finalització

2025

Import total

66217,84€

Objectius

AGAUR_Alessandra Magnani